Nautilus Biotechnology Reports Q3 2026 Net Loss of $15.6M
The company reported Q3 2026 revenue of $0.2M, operating expenses of $16.9M and cash, cash equivalents and investments of $114.3M as of Sept. 30, 2026.
Nautilus Biotechnology reported Q3 2026 revenue of $0.2M, operating expenses of $16.9M, a net loss of $15.6M, and cash, cash equivalents and investments of $114.3M as of Sept. 30, 2026.Material DetailsContext by AI AnalystThis is an early-stage earnings update for a development-stage proteomics pla…